Prevail: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Chemotherapy-naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Trial Profile

Prevail: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Chemotherapy-naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2018

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PREVAIL
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 10 Feb 2018 Results of post hoc analysis evaluating the hepatic effects of enzalutamide versus comparators in controlled castration-resistant prostate cancer trials (NCT0121299; NCT00974311; NCT01664923; NCT01288911) presented at the 2018 Genitourinary Cancers Symposium
    • 20 Nov 2017 Planned End Date changed from 28 Sep 2018 to 1 Dec 2018.
    • 30 Oct 2017 Results of an exploratory analysis assessing the the association between health-related quality of life and clinical outcomes in two phase III trials (AFFIRM and PREVAIL), published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top